Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an intravenous injection for intravenous use. It is employed to treat serious bacterial infections such as community‑acquired pneumonia, skin and soft‑tissue infections, and intra‑abdominal infections in both adult and pediatric patients under medical supervision.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated distribution channels, ensuring quality and compliance with European Union standards.

Clarithromycin is indicated for bacterial infections affecting several organ systems.

Community‑acquired pneumonia: effective in treating moderate to severe cases caused by susceptible organisms. Skin and soft‑tissue infections: used for cellulitis, abscesses, and wound infections. Intra‑abdominal infections: employed in combination therapy for peritonitis and postoperative infections.

Clarithromycin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile-associated diarrhea: severe colitis with watery stools. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - QT interval prolongation: risk of cardiac arrhythmias, especially with other QT‑prolonging drugs.

Before using Klacid, consider the following precautions to ensure safe administration. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests during therapy. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Drug interactions: review concomitant medications for CYP3A4 substrates or QT‑prolonging agents. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Clarithromycin can interact with several medicines, affecting their efficacy or safety.

Major Interactions (Avoid): - Cisapride and other QT‑prolonging drugs: may cause serious cardiac arrhythmias. - Simvastatin and other CYP3A4 substrates: increased plasma levels leading to toxicity. - Antacids containing aluminum or magnesium: reduce clarithromycin absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Carbamazepine and rifampin: induce metabolism, decreasing clarithromycin concentrations. - Oral contraceptives: may reduce hormonal efficacy, consider alternative contraception.